Metachromatic leukodystrophy (arylsulfatase A deficiency; MLD) OMIM 250100

In Metachromatic leukodystrophy (ARSA, OMIM 250100), the master switch sits on the ↓ DOWN branch ([F] forced below); the healthy state is the ON well. The forced corrective direction is to raise s toward ON branch (polarity: supply). Classification: ✓ Recovers an existing standard. Direction only — no dose, no efficacy magnitude.

The disease maps to an R19 double-well whose corrective lever is read straight off the cusp (barrier 0.5480, γ 1.4806, spinodal 0.6934). The corrective direction is forced [F]; the agent names below are direction-concordant labels at grade [O] (no dose, no efficacy or safety magnitude). This is a research hypothesis offered to experts, not medical advice.

The emergence switch

The switch for Metachromatic leukodystrophy is an R19 double-well emerged from the real proximal-promoter DNA of ARSA. Its geometry is fixed by measured stiffness γ (never fitted); the numbers below are read directly off that cusp.

emergent axis
↓ DOWN [F]
healthy branch
ON
lesion
LOF_null
γ (stiffness)
1.4806
barrier
0.5480
spinodal
0.6934
s_on / s_off
1.2168 / -1.2168
fragility
0.23
corrective polarity
supply
forced direction
raise s toward ON branch

Chemistry feasibility (DIRECTION only [O]). small-molecule recrossing of the fold is geometrically harder (barrier 0.548 at neutral drive; lower barrier = smaller drive to supply). [O] -- no affinity/potency/dose/efficacy asserted.

The derived corrective lever

The cusp forces a corrective direction: raise s toward ON branch. This is the load-bearing output of the framework — it is [F] forced, and it is falsifiable. 2 lever families are derived; the lead is h-restore (drive modulator).

h-restore (drive modulator)sign: increasegeometric rank 0.23
Mechanism. supply / restore the positive drive (replace-or-agonise the missing competence)
Applies to. allele-agnostic (downstream/environmental tilt)
favoured when the switch is fragile -- a small drive shift recrosses the fold
Falsifier. If supplying/agonising ARSA (raising the switch drive) does NOT move the DOWN [F] switch toward the healthy branch in a ARSA-deficient model, the h-restore(supply) lever is refuted for this axis.
gamma-restore (stabiliser / chaperone)sign: Nonegeometric rank 0.00
Mechanism. N/A
Applies to. none (honest exclusion)
EXCLUDED: null allele -- no product to stiffen
Falsifier. If a folding-stabiliser/chaperone does NOT re-deepen the healthy well for a residual ARSA allele (no rescue that a null allele lacks), the gamma-restore lever is refuted; null alleles are excluded by construction.

Agents mapped onto the lever

✓ Agreement with established practice. The corrective direction derived here (raise s toward ON branch) independently matches an agent already in clinical use for this disease: ex-vivo autologous ARSA-lentiviral haematopoietic stem-cell gene therapy (atidarsagene autotemcel; Lenmeldy / Libmeldy). The geometry recovered known medicine — this is a validation signal for the logic, not a new treatment claim by this kit.
Existing agents whose known action is direction-concordant with the derived lever (status as pinned in the corpus; no dose, no efficacy magnitude).
agent (class)dir.statusphasemap
ex-vivo autologous ARSA-lentiviral haematopoietic stem-cell gene therapy (atidarsagene autotemcel; Lenmeldy / Libmeldy)
Fumagalli 2022 Lancet 399:372 (atidarsagene autotemcel phase 1/2); Lenmeldy FDA approval 2024-03-18; Libmeldy EMA 2020
increaseapproved4✓ in use
intrathecal enzyme replacement therapy (recombinant human arylsulfatase A)
Dali 2020 Ann Clin Transl Neurol 7:518 (intrathecal ARSA trial)
increaseclinical3◇ in trials
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.

Direction-only candidate leads (corpus join)

Each lead is surfaced only because its known mechanism points the same way as the derived lever, and each comes with a source and a falsifier. None is a treatment.

atidarsagene autotemcel✓ recovered standarddir: increase · approved
Class. ex-vivo lentiviral ARSA HSC gene therapy
Mechanism. An autologous haematopoietic stem-cell therapy transduced ex vivo with a lentiviral vector carrying functional ARSA cDNA; engrafted cells supply arylsulfatase A and cross-correct the central nervous system, restoring the sulfatide-clearing competence the disease gene cannot provide. Direction: increase / supply the missing enzymatic competence. Engaged node: ARSA -- the therapy provides a working copy of the disease gene. Allele scope: agnostic -- supplies competence irrespective of the ARSA variant. Gene-specific to ARSA. Modality: a one-time approved ex-vivo gene therapy requiring conditioning, effective when started pre-/early-symptomatically; the supply direction recovers an approved indication.
✓ This is a rediscovery. Atidarsagene autotemcel (ex-vivo lentiviral ARSA HSC gene therapy) is approved for early metachromatic leukodystrophy; the supply direction recovered an approved indication. Requires conditioning and pre-/early-symptomatic timing -- delivery/cost barriers remain.
Safety (qualitative; no magnitude). requires myeloablative conditioning; veno-occlusive-disease and thromboembolic signals on label; haematologic-malignancy monitoring for insertional oncogenesis (qualitative; no magnitude); specialised centre; benefit is pre-/early-symptomatic only
Falsifier. If atidarsagene autotemcel (a gene-specific supply/increase agent) does NOT move the DOWN [F] switch toward the healthy branch in a ARSA-deficient model, the h-restore(supply) direction is refuted for atidarsagene autotemcel here.
Source: FDA/EMA label: atidarsagene autotemcel (Lenmeldy/Libmeldy), MLD
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.

Evidence & provenance

What is reproduced vs. cited for this page.
elementgradebasis
R19 switch & cusp geometry (this page)[V] verifiedemerged from measured promoter γ of ARSA; deterministic, 2×sha256 identical
corrective direction[F] forcedforced by the cusp sign; falsifiable (see lever falsifiers)
mapped agents / leads[O] opendirection-concordance only; corpus-pinned (2026-06-21); no dose, no efficacy/safety magnitude

Reading the agent column. VALIDATION SIGNAL -- the agent is already approved / established standard for this disease, so the direction logic recovered known clinical practice. Not a new claim by this kit. GENUINE HYPOTHESIS -- no approved indication for this disease; the direction match is a direction-only, untested [O] lead. Basis field grades the evidence (investigational here / in a related condition / off-label / speculative).